The Global Apraxia Drug Market is poised for moderate but sustained growth, driven by the increasing incidence of neurological disorders (such as stroke, neurodegenerative diseases, and brain injuries) that cause motor planning difficulties. While the mainstay of treatment for apraxia remains speech and occupational therapy, the market for pharmacological intervention—primarily focused on...